Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04799275
Title Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

diffuse large B-cell lymphoma

follicular lymphoma

diffuse large B-cell lymphoma germinal center B-cell type

B-cell lymphoma

diffuse large B-cell lymphoma activated B-cell type

MALT lymphoma

marginal zone B-cell lymphoma

lymphoplasmacytic lymphoma

Therapies

Azacitidine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: senior
Covered Countries USA


No variant requirements are available.